| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $169.3M | +32.5% |
| SG&A Expense | $59.1M | +1.9% |
| Operating Income | -$228.4M | -24.0% |
| Income Tax | $0 | — |
| Net Income | -$210.3M | -30.4% |
| EPS (Basic) | -$3.47 | -26.2% |
| EPS (Diluted) | -$3.47 | -26.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $71.2M | +12.6% |
| Short-term Investments | $284.5M | -34.0% |
| Current Assets | $362.3M | -28.3% |
| Total Assets | $396.9M | -22.5% |
| Current Liabilities | $33.2M | +16.5% |
| Long-term Debt | $30.2M | +200.5% |
| Total Liabilities | $92.9M | +140.7% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$155.5M | -33.6% |
| Capital Expenditures | $3.8M | +317.8% |
| Investing Cash Flow | $140.3M | +210.5% |
| Financing Cash Flow | $23.1M | -91.6% |
| Free Cash Flow | -$159.4M | -35.9% |
| Stockholders' Equity |
| $304.1M |
| -35.8% |